Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Grace TherapeuticsGRCE +0.95%33 3-Year EPS without NRI Growth Rate is 36.20% as of Jun. 2026, which is 50% above its 10-year median of 24.20. GuruFocus rates GRCE with a GF Score™ of 33/100. The stock has 2 warning signs investors should review. Among 1,160 Biotechnology companies, Grace Therapeutics ranks better than 73.88% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 36.20% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 33.10% per year.
During the past 10 years, the average EPS without NRI Growth Rate was 39.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Grace Therapeutics was 57.50% per year. The lowest was -26.50% per year. And the median was 24.20% per year.
Grace Therapeutics (NAS:GRCE) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Grace Therapeutics 3-Year EPS without NRI Growth Rate Related Terms
GRCE vs VERU, TVGN, MGX: 3-Year EPS without NRI Growth Rate Comparison
For the Biotechnology subindustry, Grace Therapeutics's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Grace Therapeutics 3-Year EPS without NRI Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Grace Therapeutics's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Grace Therapeutics's 3-Year EPS without NRI Growth Rate falls into.
Grace Therapeutics 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 36.20% mean?
Grace Therapeutics (GRCE) has a 3-Year EPS without NRI Growth Rate of 36.20% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Grace Therapeutics and its competitors. This is 50% above median its historical median of 24.20. According to the industry distribution chart, Grace Therapeutics ranks #303 out of 1160 companies in the Biotechnology industry, placing it in the top 26.1%.
Is Grace Therapeutics' 3-Year EPS without NRI Growth Rate too high?
Grace Therapeutics' current 3-Year EPS without NRI Growth Rate of 36.20% is 50% above median its 10-year median of 24.20. The Biotechnology industry median 3-Year EPS without NRI Growth Rate is 16.05. Grace Therapeutics' value of 36.20% is 125.5% above this industry median. Based on the distribution chart, Grace Therapeutics ranks #303 out of 1160 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Grace Therapeutics has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Grace Therapeutics' 3-Year EPS without NRI Growth Rate compare to VERU and TVGN?
According to the Biotechnology industry distribution chart, Grace Therapeutics ranks #303 out of 1160 companies for 3-Year EPS without NRI Growth Rate. This puts Grace Therapeutics in the upper half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 16.05. Grace Therapeutics' value of 36.20% is 125.5% above this benchmark. While the company's 10-year median is 24.20 vs. the industry median of 16.05, Grace Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Biotechnology company?
The median 3-Year EPS without NRI Growth Rate among Biotechnology companies is 16.05, based on 1,160 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Grace Therapeutics's current 3-Year EPS without NRI Growth Rate of 36.20% is 125.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Grace Therapeutics and its competitors. For the Biotechnology industry, the median 3-Year EPS without NRI Growth Rate is 16.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Grace Therapeutics's current 3-Year EPS without NRI Growth Rate is 36.20%, which is 50% above median its own 10-year median of 24.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grace Therapeutics stock overvalued right now?
Grace Therapeutics (GRCE) has a current 3-Year EPS without NRI Growth Rate of 36.20%. The current 3-Year EPS without NRI Growth Rate is 36.20%, which is 50% above median its 10-year median of 24.20 and 125.5% above the Biotechnology industry median of 16.05. Grace Therapeutics' overall GF Score™ is 33/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Grace Therapeutics (GRCE), the current 3-Year EPS without NRI Growth Rate is 36.20% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Grace Therapeutics Inc is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its development pipeline consists of the following product candidates: GTx-104, a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage (aSAH); GTx-102, targeted for the treatment of ataxia-telangiectasia (A-T) in a pediatric population; and GTx-101, a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia (PHN), which can be persistent and often causes debilitating pain following infection by the shingles virus. The company has one reportable operating segment: the development and commercialization of pharmaceutical applications of its patents and licensed rights.
33GF Score
Get the complete analysis for GRCE
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GRCE has been successfully added to your 
